{
    "name": "fluorouracil topical",
    "comment": "Rx",
    "other_names": [
        "Efudex",
        "Carac",
        "Fluoroplex",
        "Tolak"
    ],
    "classes": [
        "Dermatologics",
        "Other",
        "Antineoplastics",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/efudex-carac-fluorouracil-topical-343545",
    "pregnancy": {
        "common": [
            "Cases of miscarriage and birth defects (including cleft lip and cleft palate) have been reported when pregnant women were exposed to a topical or parenteral form of the drug; in addition, ventricular septal defect and cases of miscarriage occurred when pregnant women applied a topical fluorouracil product to mucous membranes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Animal reproduction studies have shown fluorouracil to be teratogenic in mice, rats, and hamsters when given at doses equivalent to the usual human intravenous dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Because many drugs are excreted in human milk and there is some systemic absorption of fluorouracil after topical administration, and because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue drug use, taking into account the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any component",
                "Women who are or may become pregnant",
                "Dihydropyrimidine Dehydrogenase (DPD) deficiency"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Potential for delayed hypersensitivity reaction to fluorouracil",
                "Occlusive dressings may increase inflammatory reaction in adjacent normal skin",
                "Possibility for increased absorption through inflamed or ulcerated skin",
                "Warn patients that the reaction in the treated areas may be unsightly during therapy and, usually, for several weeks following cessation of therapy; instruct patients to avoid exposure to ultraviolet rays during and immediately following treatment as intensity of reaction may increase",
                "The drug may be fatal if ingested by pets; avoid allowing pets to contact the drug container or the skin where drug was applied; store drug out of reach of pets; safely discard or clean any cloth or applicator that may retain the drug and avoid leaving any residues on your hands, clothing, carpeting or furniture",
                "Superficial BCC treatment only when conventional methods are impractical, since conventional methods have better response rate",
                "Application site adverse reactions (erythema, scaling/dryness, edema, crusting, erosions, stinging/burning, and pruritus) are likely to occur during and for 4 weeks after treatment of actinic keratosis on the face, ears, and/or scalp",
                "Do not apply directly into eyes, nose, mouth, or other mucous membranes because irritation, local inflammation and ulceration can occur",
                "Avoid treatment in periocular area; eye disorders, including corneal reactions have occurred with topical fluorouracil use; avoid accidental transfer of drug into eyes and to periocular area; patients should wash hands well after applying the product; if accidental exposure occurs, seek medical care",
                "Cases of miscarriage and birth defects occurred when pregnant women applied the topical form to mucous membranes; furthermore, fluorouracil interferes with synthesis of deoxyribonucleic acid (DNA), inhibits the formation of ribonucleic acid (RNA), and provokes unbalanced growth and death of cells"
            ],
            "specific": [
                {
                    "type": "Dihydropyrimidine Dehydrogenase Deficiency",
                    "description": [
                        "A large percentage of fluorouracil is catabolized by the DPD enzyme; DPD enzyme deficiency may result in increased availability of fluorouracil to the anabolic pathway, which may lead to increased interference with DNA and RNA synthesis and increased cytotoxic activity and potential toxicities",
                        "Life-threatening systemic toxicity reported with topical use of fluorouracil in a patient with DPD deficiency; patients should discontinue therapy if symptoms of fluorouracilâ€™s systemic toxicity develop"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Photosensitivity",
            "percent": null
        },
        {
            "name": "Leukocytosis",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Birth defects",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Inflammation",
            "percent": null
        },
        {
            "name": "Miscarriage",
            "percent": null
        },
        {
            "name": "Herpes simplex",
            "percent": null
        },
        {
            "name": "Allergic contact dermatits",
            "percent": null
        },
        {
            "name": "Telangectasia",
            "percent": null
        },
        {
            "name": "Hyperpigmentation",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Scarring",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        }
    ]
}